Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy
- PMID: 464648
- DOI: 10.1007/BF00412659
Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy
Abstract
Monocytopoiesis and blood monocytes were investigated in patients with superficial spreading melanoma stages I and II. Monocyte production was moderately increased in 4 of 9 untreated patients. Postoperative prophylactic BCG-vaccination gave rise to increased proliferation activity in 3 of 4 patients with previously normal monocytopoiesis. However, monocyte production returned to normal between the 4th and 6th month of BCG immunotherapy. Monocytopoietic hyperproliferation did not occur if DTIC was administered simultaneously with BCG. These results indicate that BCG-vaccination increases monocytopoiesis during the first months of treatment only. This effect is abrogated by concomitant chemotherapy.
Similar articles
-
[Studies of monocytopoiesis in patients with malignant disease and after immunostimulation with BCG, using 3H-thymidine as a DNA-label (author's transl)].Nuklearmedizin. 1982 Apr;21(2):49-54. Nuklearmedizin. 1982. PMID: 7099973 German.
-
[Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].Z Hautkr. 1982 Feb 15;57(4):294-7. Z Hautkr. 1982. PMID: 7080583 German. No abstract available.
-
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.Cancer. 1985 Feb 15;55(4):707-12. doi: 10.1002/1097-0142(19850215)55:4<707::aid-cncr2820550406>3.0.co;2-5. Cancer. 1985. PMID: 3967167 Clinical Trial.
-
The role of immunotherapy in the management of patients with malignant melanoma.World J Surg. 1979 Jul 30;3(3):309-20. doi: 10.1007/BF01556582. World J Surg. 1979. PMID: 382645 Review. No abstract available.
-
[Adjuvant therapy of malignant melanoma].Praxis (Bern 1994). 2001 Feb 22;90(8):301-6. Praxis (Bern 1994). 2001. PMID: 11256332 Review. German.